SANA - Sana Corp Forward Price-to-Revenue Multiple

sana.com (SANA) - corporate logo

The expected price-to-sales ratio of Sana Biotechnology (SANA) demonstrates a dependence on a highly specialized development portfolio for the treatment of diabetes and cancer. Strict bioethical standards and an eco-friendly approach to waste disposal ensure the issuer's stability. Its status as a recognized expert in genetic engineering strengthens the confidence of the medical community. Meanwhile, serves as the final mark for this indicator, determining the asset's current margin of safety.

sana.com - SANA Projected Price to Revenue (period 07/04/2022 - 11/14/2026)

Sana Corp - analytical breakdowns and key metrics (SANA)

- market price and analyst price targets:
Price Chart Sana Biotechnology, Inc.|SANA - Price Target Chart
- market capitalization statistics:
Market Valuation Sana Corp|SANA - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Sana Biotechnology|SANA - Book Value of Business|Market Capitalization to Book Value Ratio sana.com|SANA - Company Assets
- debt and solvency information:
Debt to Equity Sana Biotechnology|SANA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Sana Biotechnology|SANA - Company Cumulative Debt|Debt to Book Value Sana Corp|SANA - Company Long-Term Loans and Borrowings|Company Current Liabilities Sana Biotechnology|Quick Ratio sana.com
- financial results and valuation multiples details:
SANA - Final Profit|Projected Future Earnings Sana Biotechnology|SANA - Market Cap to Earnings|Future Price to Earnings Sana Bio|SANA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Sana Corp|SANA - Operating profit EBITDA|Earnings per share for the last twelve months Sana Biotechnology|SANA - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months sana.com|SANA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Sana Biotechnology
- revenue and sales proceeds data:
SANA - Company Gross Revenue|Projected Sales Volume Sana Biotechnology, Inc.|SANA - P/S Multiple|Price-to-Projected Revenue Ratio Sana Corp
Initial company analysis:Sana Biotechnology, Inc. (SANA)
Original product of Sana Corp

Sana Biotechnology focuses on developing cell therapies with minimal environmental impact and strict adherence to medical regulations. The specifics of biopharmaceuticals make business valuation dependent on future revenue streams rather than current expenditures. This indicator determines the value of one dollar of expected annual revenue, allowing for an assessment of the market premium paid for growth potential. By analyzing the forward P/S ratio, an investor can identify an entry point with an optimal margin of safety.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Corporation LEGN|Autolus Therapeutics PLC - Price-to-Projected Revenue Ratio|ALLO: Forward Price-to-Revenue Multiple|Forward Price to Sales RNAC (Selecta Biosciences Inc.)|CLLS: Forward P/S Multiple|Projected Price to Revenue cariboubio.com CRBU|TIL (Instil Bio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Genenta GNTA|Price-to-Projected Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple SNTI (Senti Biosciences)|Adaptimmune Therapeutics plc (ADAP) - Market Cap to Future Revenue Ratio|CERO: Forward Price-to-Revenue Multiple|Forward Price to Sales TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Forward Price-to-Revenue Multiple|CRGX: Price to Expected Revenue Ratio|PSTX (Poseida Therapeutics) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL